<SEC-DOCUMENT>0001558370-24-000740.txt : 20240205
<SEC-HEADER>0001558370-24-000740.hdr.sgml : 20240205
<ACCEPTANCE-DATETIME>20240205080945
ACCESSION NUMBER:		0001558370-24-000740
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240205
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240205
DATE AS OF CHANGE:		20240205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		24594004

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>chrs-20240205x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:chrs="http://www.coherus.com/20240205" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityCentralIndexKey" id="Tc_zMLIgpkx8Eys6z7Gn51VJQ_2_1">0001512762</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:AmendmentFlag" id="Tc_NWjtHslMzk657gKuc2HiSg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="chrs-20240205.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:9.77pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_eb856837_1c8f_4178_bddf_3271dfa05d43"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:DocumentType" id="Narr_Hp-IOENVYUilljpKc20fIA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_Ps5Gwp9qK0mDEQDlIVoONA"><b style="font-weight:bold;">February 5, 2024</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:24pt;font-weight:bold;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityRegistrantName" id="Narr_v3h6HUf4ikijeKja9mnvpg">COHERUS BIOSCIENCES, INC.</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_4fef730f_4ab3_41d5_9b95_011d505ca620"></a><a id="Tc_2Jsl_Sg-sECuu1ZiYsgQJw_1_0"></a><a id="Tc_EnnXkCx2fkKDQDJM9XeKyw_1_2"></a><a id="Tc_ZxWKJFy3a0iPH7w9tiHnoQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_ViYZJ8MMdkGqJRhb5oFQOA_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityFileNumber" id="Tc_DecQ2DjMXECENJ79nJpuDQ_0_2"><b style="font-size:9pt;font-weight:bold;">001-36721</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityTaxIdentificationNumber" id="Tc_50wF32kalUShrYeB_vW-VQ_0_4"><b style="font-size:9pt;font-weight:bold;">27-3615821</b></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br/><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br/><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><br/><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityAddressAddressLine1" id="Narr_O2x6EBvJpE-gruBGW2kZDw"><b style="font-weight:bold;">333 Twin Dolphin Drive</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityAddressAddressLine2" id="Narr_Te6LINPiGE-VodYjRDfjWQ"><b style="font-weight:bold;">Suite 600</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityAddressCityOrTown" id="Narr_Bo-6YczriUm9e_ALmsZguA"><b style="font-weight:bold;">Redwood City</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityAddressStateOrProvince" id="Narr_K3Stlk3L40yYyzKAmw73Hw"><b style="font-weight:bold;">CA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:EntityAddressPostalZipCode" id="Narr_HGyeNj5i8k6g43Sap7W5bw"><b style="font-weight:bold;">94065</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:CityAreaCode" id="Narr_Kfj7uwovKkSwulg46VX0BA"><b style="font-weight:bold;">650</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:LocalPhoneNumber" id="Narr_VOMc6trQaEOtbrByVBOQGw"><b style="font-weight:bold;">649-3530</b></ix:nonNumeric></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_1df92469_f3ff_4402_ae86_b7c37a7d26ea"></a><a id="Tc_3G3KF8fgkUaV1GySmJK2-A_0_1"></a><a id="Tc_wYgUodb4sUCH1m9DdpkYCA_2_1"></a><a id="Tc_EGH0FTsfJUKfDoSJLNy3Fg_4_1"></a><a id="Tc_58fGodnAbUqe8igDLiGpmA_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_GKvvEM8mUU2DWnXzCyhf3A_0_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_8HlYH25rKkSk2IdYzbTrvg_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_7AVZu8wnsUiA0DEbZ4oY1A_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_CrpBUEdsIk6kqU_1EFZ0gw_6_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_132bb9e4_a733_46a7_a748_975eae4dea5f"></a><a id="Tc_16soPQLkzEmMzFIg92WXgQ_0_0"></a><a id="Tc_EtmHUNnAHEyKexFOnTxQ-w_0_2"></a><a id="Tc_mQ80468z7kKMrSZqfPa0eg_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b><br/><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange</b><br/><b style="font-weight:bold;">on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:Security12bTitle" id="Tc_Uv-5cUX2A0-sYGFDwixYLA_1_0"><b style="font-weight:bold;">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" name="dei:TradingSymbol" id="Tc_c2zpJ6SbLECiGc0huVfR4g_1_2"><b style="font-weight:bold;">CHRS</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_C7_I_0IlLEuJrfpTFBLX2g_1_4"><b style="font-weight:bold;">The Nasdaq Global Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_5g8FBZx66Em2xHtxdt1CzQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_22e5108e_f209_447d_afc1_3b3c1f5b0eb0"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 1.01 Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">On February 5, 2024, Coherus BioSciences, Inc. (the &#8220;Company&#8221;), as borrower and on behalf of itself and certain of its subsidiaries, entered into a Consent, Partial Release and Third Amendment to Loan Agreement (the &#8220;Consent and Amendment&#8221;) with Biopharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (the &#8220;Collateral Agent&#8221;), BPCR Limited Partnership, a limited partnership established under the laws of England and Wales, as a lender (&#8220;BPCR&#8221;), and Biopharma Credit Investments V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a lender, and together with as BPCR, each, a &#8220;Lender&#8221; and collectively, the &#8220;Lenders&#8221;), pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Existing Loan Agreement and the other loan documents in connection therewith, and the parties thereto agreed to amend the previously disclosed loan agreement dated as of January 5, 2022 (as amended on April 7, 2022 and February 6, 2023, and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date of the Consent and Amendment, the &#8220;Existing Loan Agreement&#8221;) among the Company, certain of its subsidiaries, the Collateral Agent and the Lenders. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by that certain Purchase and Sale Agreement dated as of January 19, 2024 (the &#8220;Purchase Agreement&#8221;) by and between the Company and Sandoz Inc., a Delaware corporation, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the Lenders and the Collateral Agent permitted the Company to make a partial prepayment of the principal of the loans outstanding under the Existing Loan Agreement in the amount of $175,000,000 upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions and (3) the parties thereto agreed to adjust the minimum net sales covenant level under the Existing Loan Agreement. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">Other terms of the Existing Loan Agreement, as amended by the Consent and Amendment, remain generally identical to those under the Existing Loan Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">The above description of the material terms of the Consent and Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Consent and Amendment, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_515fc9bf_1cd5_4a07_af97_3efd7fb6ab3f"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">On February 5, 2024, the Company announced that it had entered into the Consent and Amendment. A copy of the press release is attached to this Current Report as Exhibit 99.1 and incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;">The information in Item 7.01 of this Current Report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_479823aa_8df5_4885_9bbb_2bde6aabd5be"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(d) Exhibits.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.53%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.3pt;"><td colspan="2" style="vertical-align:top;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:89.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:6.8pt;"><td colspan="2" style="vertical-align:top;width:10.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:24.1pt;"><td colspan="2" style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20240205xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Consent, Partial Release and Third Amendment to Loan Agreement dated as of February 5, 2024 among Coherus BioSciences, Inc., Biopharma Credit PLC, BPCR Limited Partnership and Biopharma Credit Investments V (MASTER) LP</span></a>*</p></td></tr><tr style="height:12.8pt;"><td colspan="2" style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:top;width:89.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20240205xex99d1.htm"><span style="font-style:normal;font-weight:normal;">Press Release of Coherus BioSciences, Inc., dated February 5, 2024</span></a></p></td></tr><tr style="height:12.05pt;"><td colspan="2" style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.05pt;"><td colspan="2" style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover page Interactive Data file (embedded within the Inline XBRL document)</p></td></tr><tr style="height:24.85pt;"><td style="vertical-align:top;width:3.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">*</p></td><td colspan="3" style="vertical-align:top;width:96.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Certain portions of this document that constitute confidential information have been redacted in accordance with Regulation&#160;S-K,&#160;Item 601(b)(10).</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:19.25pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f8386e8c_d5ac_40f5_8739_52c69f03d398"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.45pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: February 5, 2024</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">COHERUS BIOSCIENCES, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Dennis M. Lanfear</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Dennis M. Lanfear</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>chrs-20240205xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/5/2024 11:02:45 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">Execution Version</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CONSENT, PARTIAL RELEASE AND THIRD AMENDMENT TO LOAN AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Consent, Partial Release, Third Amendment to Loan Agreement (this &#8220;</font><b style="font-size:12pt;font-weight:bold;">Amendment</b><font style="font-size:12pt;">&#8221;), dated as of February 5, 2024 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Amendment Effective Date</b><font style="font-size:12pt;">&#8221;), is entered into by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (as &#8220;</font><b style="font-size:12pt;font-weight:bold;">Borrower</b><font style="font-size:12pt;">&#8221; and a Credit Party), the Guarantors from time to time party thereto (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Guarantor</b><font style="font-size:12pt;">&#8221; and collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Guarantors</b><font style="font-size:12pt;">&#8221;), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Collateral Agent</b><font style="font-size:12pt;">&#8221;), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales (as a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Lender</b><font style="font-size:12pt;">&#8221;) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Lender</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, Borrower, Guarantors, the Collateral Agent and the Lenders have entered into that certain Loan Agreement, dated as of January 5, 2022 (as amended by that certain First Amendment, dated as of April 7, 2022 and that certain Second Amendment and Waiver, dated as of February 6, 2023, and as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Loan Agreement</b><font style="font-size:12pt;">&#8221;) and that certain Guaranty and Security Agreement, dated as of January 5, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Security Agreement</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower intends to sell to Sandoz Inc. (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Buyer</b><font style="font-size:12pt;">&#8221;), and Buyer intends to purchase from the Borrower, pursuant to that certain Purchase and Sale Agreement dated as of January 19, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">PSA</b><font style="font-size:12pt;">&#8221;), all of the issued and outstanding Interests (as defined in the PSA) of Coherus Ophthalmology, LLC, a Delaware limited liability company and a Guarantor (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Ophthalmology</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, in connection with the consummation of the transactions contemplated by the PSA and the other Transaction Documents (as defined in the PSA) (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Ophthalmology Transactions</b><font style="font-size:12pt;">&#8221;) and pursuant to Section 6.15 of the PSA, the Borrower and Buyer intend to enter into the Transition Services Agreement (as defined in the PSA), pursuant to which the Borrower or its Subsidiaries will provide, or cause to be provided, to Buyer certain services on a transitional basis, including providing access to data and other acts in furtherance of the Ophthalmology Transactions (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Transition Services</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower requests release of </font><font style="font-size:12pt;">Ophthalmology </font><font style="font-size:12pt;">from its obligations under the Loan Documents to which it is a party and release of </font><font style="font-size:12pt;">the Liens and security interest granted to the Collateral Agent on the Equity Interest of Ophthalmology and on the assets owned by Ophthalmology (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Ophthalmology Release</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower intends to dispose or otherwise Transfer to a third party such assets as are set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex I</u><font style="font-size:12pt;"> attached hereto (such Transfers, together with the Ophthalmology Transactions, collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Transactions</b><font style="font-size:12pt;">&#8221;) and requests release of the Liens and security interest granted to the Collateral Agent on such assets (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Asset Release</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the consummation of the Transactions requires disposition of certain portion of the Collateral, the direct or indirect Transfer of which is prohibited under Section 6.1 of the Loan Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower intends to prepay on the later of April 1, 2024 and two (2) Business Days following the Closing Date (as defined in the PSA), outstanding principal amounts under the Term Loans in the amount of $175,000,000 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Term Loan Prepayment</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, such Term Loan Prepayment constitutes a prepayment in part, and not in whole, of the outstanding principal amounts under the Term Loans and, consequently, is prohibited under Section 2.2(c) of the Loan Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower requests certain additional releases as set forth in Part 1 of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex III</u><font style="font-size:12pt;"> attached hereto (collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Specified Releases</b><font style="font-size:12pt;">&#8221;, and together with the Ophthalmology Release and the Asset Release, collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Releases</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, </font><font style="font-size:12pt;">notwithstanding anything to the contrary set forth in the Loan Documents, including the requirements set forth in Section 2.2(c) and Section 6.1 of the Loan Agreement, the Borrower has requested that the Required Lenders and Collateral Agent consent, and the Required Lenders and Collateral Agent have agreed to consent, on the terms and subject to the conditions set forth herein, to (a) the Transactions (including the Borrower&#8217;s or any of its Subsidiary&#8217;s performance of the Transition Services), (b) the Term Loan Prepayment and (c) the Releases (such consent, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Specified Consent</b><font style="font-size:12pt;">&#8221;)</font><font style="font-size:12pt;">; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, in accordance with Section 11.5 of the Loan Agreement, Borrower (acting for its own behalf and on behalf of the other Credit Parties), Collateral Agent and the Lenders desire to amend the Loan Agreement on the terms and conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AGREEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions; Interpretation</u><font style="font-size:12pt;">. &#160;All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. &#160;The rules of interpretation set forth in the first paragraph of Section 13.1 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent, Limited Release and Amendments to Loan Agreement</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The Required Lenders and the Collateral Agent hereby consent to the consummation of the Transactions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Required Lenders and the Collateral Agent hereby (i) release Ophthalmology from its obligations under each Loan Document to which it is a party, (ii) release the Liens and security interest granted to the Collateral Agent on the Equity Interest of Ophthalmology and on the assets owned by Ophthalmology, (iii) authorize the Borrower, the Buyer and any of their designees to file a UCC amendment to evidence such release and (iv) agree to execute and deliver such other release documents reasonably requested in writing by the Borrower or the Buyer to evidence such release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The Collateral Agent hereby (i) releases the Liens and security interest granted to the Collateral Agent on such assets as set forth in Part 1 of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex III</u><font style="font-size:12pt;"> attached hereto and consents to the Transfer of any such assets, (ii) releases certain obligations as set forth in Part 1 of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex III</u><font style="font-size:12pt;"> attached hereto, (iii) authorizes the Borrower and any of its designees to file a UCC amendment to evidence such release and (iv) agrees to execute and deliver such other release documents reasonably requested in writing by the Borrower to evidence such release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">The Required Lenders and the Collateral Agent hereby consent to the Term Loan Prepayment; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:12pt;">, that the Closing Date (as defined in the PSA) occurs and the Term Loan Prepayment occurs on the later of two (2) Business Days thereafter and April 1, 2024; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u><font style="font-size:12pt;">, that the Term Loan Prepayment shall be applied to the outstanding Term Loans in such amounts as the Required Lenders determine in their sole discretion (and the Collateral Agent shall notify Borrower in writing regarding such application and the principal amount of the Term Loans which remain outstanding as a result thereof); </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u><font style="font-size:12pt;">, that the Term Loan Prepayment shall be accompanied by any and all accrued and unpaid interest thereon through the date of such Term Loan Prepayment, and any and all amounts payable in connection with such Term Loan Prepayment pursuant to Section 2.2(e), Section 2.2(f) (as applicable) and Section 2.4 of the Loan Agreement; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">finally</u><font style="font-size:12pt;">, that, notwithstanding anything in Section 2.2(e) or Section 2.2(f) of the Loan Agreement to the contrary:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:40.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the Makewhole Amount payable with respect to the Term Loan Prepayment shall be the average of (x) the Makewhole Amount payable with respect to such Term Loan Prepayment calculated as if such Term Loan Prepayment is applied first to the Tranche A Loan until repaid in full, second to the Tranche B Loan until repaid in full, and third to the Tranche D Loan until repaid in full and (y) the Makewhole Amount payable with respect to such Term Loan Prepayment calculated as if such Term Loan Prepayment is applied first to the Tranche D Loan until repaid in full, second to the Tranche B Loan until repaid in full and third to the Tranche A Loan until repaid in full; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:40.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the Prepayment Premium payable with respect to the Term Loan Prepayment shall be the average of (x) the Prepayment Premium payable with respect to such Term Loan Prepayment calculated as if such Term Loan Prepayment is applied first to the Tranche A Loan until repaid in full, second to the Tranche B Loan until repaid in full, and third to the Tranche D Loan until repaid in full and (y) the Prepayment Premium payable with respect to such Term Loan Prepayment calculated as if such Term Loan Prepayment is applied first to the Tranche D Loan until repaid in full, second to the Tranche B Loan until repaid in full and third to the Tranche A Loan until repaid in full.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">The Loan Agreement shall be amended by deleting in its entirety Section 6.15 of the Loan Agreement and replacing it as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.15 </b></font><b style="font-size:12pt;font-weight:bold;">Minimum Net Sales</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">From and after the Third Amendment Effective Date and without violating any other term or provision of this Agreement, permit the trailing twelve-month Net Sales, tested quarterly at the end of each fiscal quarter commencing with the first full fiscal quarter occurring after the Third Amendment Effective Date and continuing through the fiscal quarter ending December 31, 2026, to be less than $125,000,000. &#160;For the avoidance of doubt, the amount of Net Sales of Product described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (d)</u><font style="font-size:12pt;"> of the definition thereof shall be included in calculation of Net Sales for purposes of determining compliance with this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.15(a)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">From and after the Third Amendment Effective Date and without violating any other term or provision of this Agreement, permit the trailing twelve-month Net Sales of Product described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (d)</u><font style="font-size:12pt;"> of the definition thereof, tested quarterly at the end of each fiscal quarter commencing on quarter ending December 31, 2024, to be less than the applicable amount set forth on </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex II</u><font style="font-size:12pt;"> to the Third Amendment.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">The Loan Agreement shall be amended by deleting in its entirety sub-clause (ii) of Section 7.2(a) of the Loan Agreement and replacing it as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;(ii)</font></font><font style="font-size:12pt;">violates or breaches any covenant or agreement in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u><font style="font-size:12pt;"> (including, for the avoidance of doubt, violations or breaches of the mandatory prepayment requirement set forth in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (q)</u><font style="font-size:12pt;"> of the definition of Permitted Transfers) or the requirement to make the Term Loan Prepayment (as defined in the Third Amendment) on the later of April 1, 2024 and two (2) Business Days following the Closing Date (as defined in the PSA (as defined in the Third Amendment));&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><font style="font-size:12pt;">The Loan Agreement shall be amended by re-numbering clause (q) of the definition of Permitted Transfers in Section 13.1 of the Loan Agreement as clause (r), and adding the following as new clause (q) of the definition of Permitted Transfers in Section 13.1 of the Loan Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8220;(q)</font></font><font style="font-size:12pt;">Transfers of any of the assets or properties described in Annex I to the Third Amendment, but only so long as (i) Borrower or such Subsidiary shall promptly, and in any event no later than three (3) Business Days thereafter, notify the Collateral Agent in writing of the occurrence of such Transfer and the cash proceeds therefrom, and (ii) notwithstanding anything in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)(i)</u><font style="font-size:12pt;"> to the contrary, Borrower or such Subsidiary shall, no later than two (2) Business Days following the date on which Borrower or such Subsidiary receives cash proceeds of any such Transfer(s), individually or in the aggregate, of more than $10,000,000, prepay the Term Loans in an amount equal to (x) the cash proceeds of such Transfer(s) in excess of $10,000,000 (</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, that the amount of such excess is greater than or equal to $1,000,000), net of (1) any Taxes thereon, (2) expenses actually incurred in connection therewith and (3) any then-outstanding and noncancelable</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">obligations under contract manufacturing organization contracts (but only to the extent not previously netted from such cash proceeds received, to avoid any double-counting); </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, that such prepayment shall be applied to the outstanding Term Loans in such amounts as the Required Lenders determine in their sole discretion (and the Collateral Agent shall notify Borrower in writing regarding such application and the principal amount of the Term Loans which remain outstanding as a result thereof). &#160;Any prepayment required to be made pursuant to this </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (q)</u><font style="font-size:12pt;"> shall be accompanied by any and all amounts payable in connection with such prepayment pursuant to </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(e)</u><font style="font-size:12pt;"> and </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(f)</u><font style="font-size:12pt;"> (as applicable) </font><font style="font-size:12pt;">and Section 2.4 of the Loan Agreement; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, that, notwithstanding anything in Section 2.2(e) or Section 2.2(f) of the Loan Agreement to the contrary:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:40.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the Makewhole Amount payable with respect to such prepayment shall be the average of (x) the Makewhole Amount payable with respect to such prepayment calculated as if such prepayment is applied first to the Tranche A Loan until repaid in full, second to the Tranche B Loan until repaid in full, and third to the Tranche D Loan until repaid in full and (y) the Makewhole Amount payable with respect to such prepayment calculated as if such prepayment is applied first to the Tranche D Loan until repaid in full, second to the Tranche B Loan until repaid in full and third to the Tranche A Loan until repaid in full; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:40.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">the Prepayment Premium payable with respect to such prepayment shall be the average of (x) the Prepayment Premium payable with respect to the Term Loan Prepayment calculated as if such prepayment is applied first to the Tranche A Loan until repaid in full, second to the Tranche B Loan until repaid in full, and third to the Tranche D Loan until repaid in full and (y) the Prepayment Premium payable with respect to such prepayment calculated as if such prepayment is applied first to the Tranche D Loan until repaid in full, second to the Tranche B Loan until repaid in full and third to the Tranche A Loan until repaid in full.</font><font style="font-size:12pt;">&#8221;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><font style="font-size:12pt;">The Loan Agreement shall be amended by adding, in alphabetical order, the following definitions to Section 13.1 of the Loan Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">&#8220;&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Amendment</b><font style="font-size:12pt;">&#8221; means that certain </font><font style="font-size:12pt;">Consent, Partial Release, Third Amendment to Loan Agreement, dated as of the Third Amendment Effective Date, by and among Borrower, the Collateral Agent and the Lenders party thereto.</font><font style="font-size:12pt;">&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">&#8220;&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Amendment Effective Date</b><font style="font-size:12pt;">&#8221; means February 5, 2024.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">The Loan Agreement shall be amended as set forth in Part 2 of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex III</u><font style="font-size:12pt;"> attached hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(j)</font></font><font style="font-size:12pt;">Effective upon the occurrence of the Term Loan Prepayment, the Loan Agreement shall be amended by deleting in its entirety each of clause (c) of the definition of &#8220;Product&#8221; and clause (c) of the definition &#8220;Specified Product&#8221; in Section 13.1 of the Loan Agreement and replacing each with &#8220;[reserved].&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(k)</font></font><font style="font-size:12pt;">The parties hereto agree that the Transfers contemplated by the Ophthalmology Transactions shall be deemed to be Permitted Transfers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(l)</font></font><font style="font-size:12pt;">The parties hereto agree that, so long as the Closing Date (as defined in the PSA) occurs, the failure of Borrower or the applicable Subsidiary to make the Term Loan Prepayment on the later of two (2) Business Days following the Closing Date (as defined in the PSA) and April 1, 2024 shall constitute an Event of Default under the Loan Agreement in respect of which cure periods provided under Section 7.2(b) of the Loan Agreement shall not apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(m)</font></font><font style="font-size:12pt;">The parties hereto agree that, so long as any Transfers of any of the assets or properties described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex I</u><font style="font-size:12pt;"> to this Amendment are consummated, the failure of Borrower or the applicable Subsidiary to make the mandatory prepayment required pursuant to </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (q)</u><font style="font-size:12pt;"> of the definition of Permitted Transfers in Section 13.1 of the Loan Agreement (as amended by this Amendment) shall constitute an Event of Default under the Loan Agreement in respect of which cure periods provided under Section 7.2(b) of the Loan Agreement shall not apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 3.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties; Reaffirmation</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Borrower hereby represents and warrants to each Lender and the Collateral Agent as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">Borrower has all requisite power and authority to enter into this Amendment and to carry out the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:12pt;">This Amendment has been duly executed and delivered by Borrower and is the legally valid and binding obligation of such Person, enforceable against such Person in accordance with its respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&#8217; rights generally or by general principles of equity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iii)</font></font><font style="font-size:12pt;">The execution, delivery and performance by Borrower of this Amendment have been duly authorized and do not and will not: (A) contravene the terms of such Person&#8217;s Operating Documents; (B) violate any Requirements of Law, except to the extent that such violation could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (C) conflict with or result in any breach or contravention of, or require any payment to be made under any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or affecting such Person or the assets or properties of such Person or any of its Subsidiaries or any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which such Person or any of its properties or assets are subject, except to the extent that such conflict, breach, contravention or payment could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (D) require any Governmental Approval, or other action by, or notice to, or filing with, any Governmental Authority (except such Governmental Approvals or other actions, notices and filings which have been duly obtained, taken, given or made on or before the Third Amendment Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (E) require any approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Person other than a Governmental Authority, including such Person&#8217;s stockholders, members or partners, (except such approvals, consents, exemptions, authorizations, actions, notices and filings which have been or will be duly obtained, taken, given or made on or before the Third Amendment Effective Date and are in full force and effect), except</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; or (F) constitute a material breach of or a material default under (which such default has not been cured or waived) or an event of default (or the equivalent thereof, however described) under, or could reasonably be expected to give rise to the cancellation, termination or invalidation of or the acceleration of such Person&#8217;s or any Subsidiary&#8217;s obligations under, any Material Contract</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iv)</font></font><font style="font-size:12pt;">Both before and immediately after giving effect to this Amendment, no Event of Default or Default has occurred and is continuing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Borrower hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. &#160;By executing this Amendment, Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">References to and Effect on Loan Agreement</u><font style="font-size:12pt;">. &#160;Except as specifically set forth herein, this Amendment shall not modify or in any way or affect any of the terms, conditions, covenants, representations and warranties contained in the Loan Agreement, or any of the rights of the Lenders and the Collateral Agent therein, which shall remain in full force and effect and is hereby ratified and confirmed in all respects. Except as specifically set forth herein, the execution, delivery and effectiveness of this Amendment shall not directly or indirectly (i) constitute a consent or waiver of any past, present or future breaches, violations or defaults of or under any provisions of the Loan Agreement nor constitute a novation of any of the Obligations under the Loan Agreement, (ii) amend, modify or operate as a waiver of any provision of the Loan Agreement or any right, power or remedy of any Lender or the Collateral Agent, or (iii) constitute a course of dealing or other basis for altering the Loan Agreement or any other Loan Document. &#160;Except as set forth herein, each of the Lenders and the Collateral Agent reserves all of its rights, powers, and remedies under the Loan Documents and Requirements of Law. &#160;Each of the Credit Parties acknowledges and agrees that the Specified Consent does not in any manner whatsoever limit any right of any of the Lenders or the Collateral Agent to insist upon strict compliance by Borrower with the Loan Agreement (as amended by this Amendment).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 5.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u><font style="font-size:12pt;">. &#160;This Amendment binds and is for the benefit of Borrower, the other Credit Parties, Lenders and Collateral Agent and each of their respective successors and permitted assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Venue; Jury Trial Waiver</u><font style="font-size:12pt;">. &#160;This Amendment shall be construed in accordance with and governed by the law of the State of New York. The provisions of Section 10 (</font><i style="font-size:12pt;font-style:italic;">Choice of Law, Venue and Jury Trial Waiver</i><font style="font-size:12pt;">) of the Loan Agreement shall apply hereto as if more fully set forth herein as if references therein to &#8220;this Agreement&#8221; were references to this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">SECTION 7. </font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-size:12pt;">. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or other electronic imaging means (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">counterpart of this Amendment. &#160;The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in this Amendment shall be deemed to include electronic signatures or electronic records, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for under any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[Remainder of Page Intentionally Left Blank]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:12pt;">, each of the undersigned has caused this Amendment to be duly executed and delivered as of the date first above written.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">COHERUS BIOSCIENCES, INC.,</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">as Borrower and a Credit Party,</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">on its own behalf and on behalf of each other Credit Party</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:51.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Dennis M. Lanfear</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Dennis M. Lanfear</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">Signature Page to Consent and Third Amendment</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">BIOPHARMA CREDIT PLC,</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">as Collateral Agent</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Pharmakon Advisors, LP,</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">its Investment Manager</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">By: Pharmakon Management I, LLC,</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">its General Partner</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By</font></p></td><td style="vertical-align:top;width:51.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Pedro Gonzalez de Cosio</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Pedro Gonzalez de Cosio</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Managing Member</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">BPCR LIMITED PARTNERSHIP,</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">as a Lender</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Pharmakon Advisors, LP,</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">its Investment Manager</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">By: Pharmakon Management I, LLC,</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">its General Partner</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By</font></p></td><td style="vertical-align:top;width:51.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Pedro Gonzalez de Cosio</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Pedro Gonzalez de Cosio</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Managing Member</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP,</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">as a Lender</b></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:57.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Pharmakon Advisors, LP,</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">its Investment Manager</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">By: Pharmakon Management I, LLC,</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">its General Partner</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By</font></p></td><td style="vertical-align:top;width:51.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Pedro Gonzalez de Cosio</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Pedro Gonzalez de Cosio</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:51.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Managing Member</font></p></td><td style="vertical-align:top;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">Signature Page to Consent and Third Amendment</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ANNEX I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ANNEX II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ANNEX III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>chrs-20240205xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/5/2024 11:02:45 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:20pt;line-height:1.18;background:#ffffff;margin:0pt;"><img src="chrs-20240205xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:53.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:216.72pt;"></p><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.43;margin:0pt;"><a name="_z7yconokz22h"></a><font style="font-family:'Segoe UI';font-size:10.5pt;font-weight:bold;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 -</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">- Revenue covenant reduced to $125 million -</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">- Term loan annual interest expense projected to be reduced by ~70% -</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">REDWOOD CITY, Calif.,&#160;February 5, 2024&#160;--&#160;Coherus BioSciences, Inc.&#160;(&#8220;Coherus,&#8221; NASDAQ: CHRS) today announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement entered in January 2022. Following the closing of the previously announced divestiture of the ophthalmology franchise to Sandoz, Coherus plans to prepay $175 million of $250 million principal balance in Q2 2024, leaving a residual balance of $75 million and reducing projected annual interest payments by about 70%.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#8220;The divestiture of the ophthalmology franchise, when completed, is projected to provide us with the opportunity to improve our capital structure and reduce interest payment obligations by paying down a significant portion of the principal on term loan debt while renegotiating certain terms,&#8221; said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. &#8220;This will allow us to move forward with a strengthened balance sheet, supporting sustainable revenue growth in our oncology business and better aligning with our sharpened focus as an oncology innovator.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#8220;Coherus has done a great job navigating past the adverse macro developments beyond their control which were impacting their business,&#8221; said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP. &#8220;With three UDENYCA formats in the pegfilgrastim market, the launch of LOQTORZI into nasopharyngeal carcinoma, plus a promising immuno-oncology pipeline, they have positioned themselves for success as an oncology company. Pharmakon is happy to be a part of their growth and transition.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by that certain Purchase and Sale Agreement dated as of January 19, 2024 (the &#8220;Purchase Agreement&#8221;) by and between the Company and Sandoz Inc., a Delaware corporation, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the Lenders and the Collateral Agent permitted the Company to make a partial prepayment of the principal of the loans outstanding under the Existing Loan Agreement in the amount of $175,000,000 upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions and (3) the parties thereto agreed to adjust the minimum net sales covenant level under the Existing Loan Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Other terms of the Existing Loan Agreement, as amended by the Consent and Amendment, remain generally identical to those under the Existing Loan Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">For background, please see the announcement of the Existing Loan Agreement at  https://investors.coherus.com/news-releases/news-release-details/coherus-biosciences-secures-credit-financing-pharmakon-advisors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">About&#160;Coherus BioSciences</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that will be synergistic with its proven commercial capabilities in oncology.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Coherus&#8217; immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel anti-IL-27 antibody currently being evaluated in two ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, ADCC-enhanced anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the novel pathway ILT4 with an IND filing planned in the first half of 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Coherus markets LOQTORZI&#8482; (toripalimab-tpzi), a novel next generation PD-1 inhibitor, UDENYCA&#174; (pegfilgrastim-cbqv), a biosimilar of Neulasta&#174;, CIMERLI&#174; (ranibizumab-eqrn), a biosimilar of Lucentis&#174;, and YUSIMRY&#8482; (adalimumab-aqvh), a biosimilar of Humira&#174;.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding how Coherus will use the proceeds from the divestiture; whether Coherus&#8217; oncology business will continue to grow; and whether the closing of the divestiture will occur and the timing of such closing. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus&#8217; actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties inherent in the clinical drug development process; risks related to our existing and potential collaboration partners; risks of the drug development position of Coherus&#8217; competitors; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus&#8217; business; the timing of Coherus&#8217; regulatory filings; the risk of FDA review issues; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus&#8217; drug candidates; the risk that Coherus is unable to close the divestiture at all or without incurring substantial costs and other resources; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">statements, as well as risks relating to Coherus&#8217; business in general, see Coherus&#8217; Quarterly Report on Form 10-Q for the quarter ended&#160;September 30, 2023, filed with the&#160;Securities and Exchange Commission&#160;on&#160;November 6, 2023, including the section therein captioned &#8220;Risk Factors&#8221; and in other documents that Coherus files with the&#160;Securities and Exchange Commission.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Coherus Contact Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Investors:<font style="color:#0a0a0a;"><br></font>Jami Taylor<font style="color:#0a0a0a;">, Head of Investor Relations for&#160;</font>Coherus<font style="color:#0a0a0a;"><br></font>IR@coherus.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Media:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Jodi Sievers, VP Corporate Communications<br>media@coherus.com</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>chrs-20240205xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20240205xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( 2$# 2(  A$! Q$!_\0
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MRZF4?-+(ZAN3W !P/85Y1^U=\*Y9/"NAZQH\#/;Z);BSFB09*0#&QOHO(/\
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MV#)/_1T5?9-<7%-6<L=[-OW4E9>IZ7 .'I0RGVT8^]*3N^KMLO3R/AGX@_\
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>chrs-20240205.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/5/2024 11:02:50 AM-->
<!--Modified on: 2/5/2024 11:02:50 AM-->
<xsd:schema targetNamespace="http://www.coherus.com/20240205" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:chrs="http://www.coherus.com/20240205">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20240205_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20240205_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20240205_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>chrs-20240205_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/5/2024 11:02:50 AM-->
<!--Modified on: 2/5/2024 11:02:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="chrs-20240205.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>chrs-20240205_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/5/2024 11:02:50 AM-->
<!--Modified on: 2/5/2024 11:02:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>chrs-20240205_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/5/2024 11:02:50 AM-->
<!--Modified on: 2/5/2024 11:02:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="chrs-20240205.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638427277701254927" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638427277701254927" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638427277701254927" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638427277701254927" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638427277701254927" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638427277701254927" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638427277701254927" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638427277701254927" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638427277701254927" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638427277701254927" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_638427277701254927" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_638427277701254927" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638427277701254927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638427277701254927" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638427277701267036" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638427277701267036" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638427277701267036" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638427277701267036" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638427277701267036" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638427277701267036" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638427277701267036" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638427277701267036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638427277701267036" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638427277701274945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638427277701274945" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638427277701274945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638427277701274945" order="23" use="optional" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140230224172240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COHERUS BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  05,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ -4%%6&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( #5!15A,0_,:[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #5!15B97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ -4%%6#-T;32&!   :Q$  !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #5!15B?H!OPL0(
M .(,   -              "  <H,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "H4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="chrs-20240205x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chrs-20240205.xsd</File>
    <File>chrs-20240205_def.xml</File>
    <File>chrs-20240205_lab.xml</File>
    <File>chrs-20240205_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="chrs-20240205x8k.htm">chrs-20240205x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "chrs-20240205x8k.htm": {
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20240205",
   "dts": {
    "schema": {
     "local": [
      "chrs-20240205.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "chrs-20240205_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20240205_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20240205_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "chrs-20240205x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20240205x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20240205x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001558370-24-000740-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-000740-xbrl.zip
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M/ZJG!NE1\:R7RZ[(&<F\G^-@K.E\.VXO?=I.%'"%H)V,Z4NLBM7:#:1=#9>
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MSHHL;HELIM!4ZH'\Y;:0^H(PWB#OTGTNY4YL==ZI/;E+YS]02P,$%     @
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MLO9_?C6\N+*VE:/;7S -_P502P,$%     @ -4%%6,Z([<H,&0  2K(  !0
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MX+@U67"#3S!H 5YGVNC4=TT\JMF.35@#.JRQWH@775)=)S:_A ;'H44\JD5
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M#[IB=Z9ER[9_7#>&DG%]T#QK[A]5?Y"#$6LI3;?\.?Q^L+\SDK% 3_?*@VI
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M@Y.%P;%B'5WTJ:>C\='YS.TY=( A8[F9@I=WQ;\<?Y- '_E>@+#;Q^"QHP;
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MB5F$ZNQ6@O<PB'S9E?#M!,472[B4*"=H/ QU8-1]J/(ITWY!@5:BH.8*984
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MIDLK3!76EKCE%(0W^QSP\/J/9[07;+.9^MHM*L",5Q""?5?6GW</XQZSVWO
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MUEA -_I2=%E3@;IN!#OO=J4GG)C^5#Z*5R4=5@0JL)JI_A6 VDR%<AV\T;"
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MLO"C#]RTU-PTPA'PPSJ;NJ$J321"C<:H2QOF@E$65&N6JG6..WCH7/"B\4+
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M4$L! A0#%     @ -4%%6"0R?SPE P  5@P  !4              ( !& 0
M &-H<G,M,C R-# R,#5?9&5F+GAM;%!+ 0(4 Q0    ( #5!15C\WSB]@@4
M ",^   5              "  7 '  !C:')S+3(P,C0P,C U7VQA8BYX;6Q0
M2P$"% ,4    "  U0458N,R,"-0$  #O*0  %0              @ $E#0
M8VAR<RTR,#(T,#(P-5]P<F4N>&UL4$L! A0#%     @ -4%%6,Z([<H,&0
M2K(  !0              ( !+!(  &-H<G,M,C R-# R,#5X.&LN:'1M4$L!
M A0#%     @ -4%%6!'*9ZVW)   #J0! !@              ( !:BL  &-H
M<G,M,C R-# R,#5X97@Q,&0Q+FAT;5!+ 0(4 Q0    ( #5!15A<)7_*B \
M !@\   8              "  5=0  !C:')S+3(P,C0P,C U>&5X.3ED,2YH
8=&U02P4&      < !P#6 0  %6

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>chrs-20240205x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="chrs-20240205.xsd" xlink:type="simple"/>
    <context id="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_zMLIgpkx8Eys6z7Gn51VJQ_2_1">0001512762</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_NWjtHslMzk657gKuc2HiSg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_Hp-IOENVYUilljpKc20fIA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_Ps5Gwp9qK0mDEQDlIVoONA">2024-02-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_v3h6HUf4ikijeKja9mnvpg">COHERUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_ViYZJ8MMdkGqJRhb5oFQOA_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_DecQ2DjMXECENJ79nJpuDQ_0_2">001-36721</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_50wF32kalUShrYeB_vW-VQ_0_4">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_O2x6EBvJpE-gruBGW2kZDw">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_Te6LINPiGE-VodYjRDfjWQ">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_Bo-6YczriUm9e_ALmsZguA">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_K3Stlk3L40yYyzKAmw73Hw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_HGyeNj5i8k6g43Sap7W5bw">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_Kfj7uwovKkSwulg46VX0BA">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_VOMc6trQaEOtbrByVBOQGw">649-3530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_GKvvEM8mUU2DWnXzCyhf3A_0_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_8HlYH25rKkSk2IdYzbTrvg_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_7AVZu8wnsUiA0DEbZ4oY1A_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_CrpBUEdsIk6kqU_1EFZ0gw_6_0">false</dei:PreCommencementTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_Uv-5cUX2A0-sYGFDwixYLA_1_0">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_c2zpJ6SbLECiGc0huVfR4g_1_2">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Tc_C7_I_0IlLEuJrfpTFBLX2g_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_5_2024_To_2_5_2024_Sieosr_rzEqHRAg5pHYp3g"
      id="Narr_5g8FBZx66Em2xHtxdt1CzQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
